Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
Background: The aim of this study is to evaluate the pharmacoeconomic profile of adding enzalutamide to first-line treatment for metastatic, hormone-sensitive prostate cancer (mHSPC) from the US and Chinese payers' perspectives.Materials and Methods: A Markov model with three health states: pro...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Frontiers Media S.A.
2021-02-01
|
| Edice: | Frontiers in Public Health |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fpubh.2021.608375/full |